Nearly half of the head and neck cancer cases are diagnosed in late stages. Traditional screening modalities have many disadvantages. The aim of the present article was to review the scientific literature about novel head and neck cancer diagnostics - epigenetic biomarkers.
EVIDENCE ACQUISITION:
A comprehensive review of the current literature was conducted according to the PRISMA guidelines by accessing the NCBI PubMed database. Authors conducted the search of articles in English language published from 2004 to 2015.
EVIDENCE SYNTHESIS:
A total of thirty three relevant studies were included in the review. Fifteen of them concerned DNA methylation alterations, nine evaluation of abundancies in histone expressions and nine miRNA expression changes in HNC.
CONCLUSIONS:
Considerable number of epigenetic biomarkers have been identified in both tumor tissue and salivary samples. Genes with best diagnostic effectiveness rates and further studying prospects were: TIMP3, DCC, DAPK, CDH1, CCNA1, AIM1, MGMT, HIC1, PAX1, PAX5, ZIC4, p16, EDNRB, KIF1A, MINT31, CD44, RARβ , ECAD. Individual histone and miRNA alterations tend to be hnc specific. Prognostic values of separate biomarkers are ambiguous. No established standards for molecular assay of head and neck cancer was found in order to elude the paradoxical results and discrepancies in separate trials.
NicoteraG., Di StasioS.M. and AngelilloI.F., Knowledge and behaviors of primary care physicians on oral cancer in Italy, Oral Oncol40 (2004), 490-5.
2.
van der WaalI., de BreeR., BrakenhoffR. and CoeberghJ.W., Early diagnosis in primary oral cancer: is it possible? Med Oral Patol Oral Cir Bucal16 (2011), e300-5.
3.
SmailyteG., Cancer incidence among workers exposed to softwood dust in Lithuania, Occup Environ Med69 (2012), 449-51.
4.
BonifaziM., MalvezziM., BertuccioP., EdefontiV., GaravelloW., LeviF., La VecchiaC. and NegriE., Age-period-cohort analysis of oral cancer mortality in Europe: the end of an epidemic? Oral Oncol47 (2011), 400-7.
5.
FranzmannE.J., ReateguiE.P., PedrosoF., PernasF.G., KarakullukcuB.M., CarrawayK.L., HamiltonK., SingalR. and GoodwinW.J., Soluble CD44 is a potential marker for the early detection of head and neck cancer, Cancer Epidemiol Biomarkers Prev16 (2007), 1348-55.
6.
LiuJ. and DuanY., Saliva: a potential media for disease diagnostics and monitoring, Oral Oncol48 (2012), 569-77.
7.
VietC.T. and SchmidtB.L., Understanding oral cancer in the genome era, Head Neck32 (2010), 1246-68.
8.
MoherD., LiberatiA., TetzlaffJ., AltmanD.G. and GroupP., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, BMJ339 (2009), b2535.
9.
HigginsJ.P., AltmanD.G., GotzscheP.C., JuniP., MoherD., OxmanA.D., SavovicJ., SchulzK.F., WeeksL., SterneJ.A.,Cochrane Bias MethodsG. and Cochrane Statistical MethodsG., The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ343 (2011), d5928.
10.
JiangJ., LeeE.J., GusevY. and SchmittgenT.D., Real-time expression profiling of microRNA precursors in human cancer cell lines, Nucleic Acids Res33 (2005), 5394-403.
11.
DikshitR.P., Gillio-TosA., BrennanP., De MarcoL., FianoV., Martinez-PenuelaJ.M., BoffettaP. and MerlettiF., Hypermethylation, risk factors, clinical characteristics, and survival in 235 patients with laryngeal and hypopharyngeal cancers, Cancer110 (2007), 1745-51.
12.
NagataS., HamadaT., YamadaN., YokoyamaS., KitamotoS., KanmuraY., NomuraM., KamikawaY., YonezawaS. and SugiharaK., Aberrant DNA methylation of tumor-related genes in oral rinse: a noninvasive method for detection of oral squamous cell carcinoma, Cancer118 (2012), 4298-308.
13.
RighiniC.A., de FraipontF., TimsitJ.F., FaureC., BrambillaE., ReytE. and FavrotM.C., Tumor-specific methylation in saliva: a promising biomarker for early detection of head and neck cancer recurrence, Clin Cancer Res13 (2007), 1179-85.
14.
DemokanS., ChangX., ChuangA., MydlarzW.K., KaurJ., HuangP., KhanZ., KhanT., OstrowK.L., BraitM., HoqueM.O., LiegeoisN.J., SidranskyD., KochW. and CalifanoJ.A., KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses, Int J Cancer127 (2010), 2351-9.
15.
PattaniK.M., ZhangZ., DemokanS., GlazerC., LoyoM., GoodmanS., SidranskyD., BermudezF., Jean-CharlesG., McCaffreyT., PadhyaT., PhelanJ., SpivakovskyS., BowneH.Y., GoldbergJ.D., RolnitzkyL., RobbinsM., KerrA.R., SiroisD. and CalifanoJ.A., Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy, Cancer Prev Res (Phila)3 (2010), 1093-103.
16.
CarvalhoA.L., JeronimoC., KimM.M., HenriqueR., ZhangZ., HoqueM.O., ChangS., BraitM., NayakC.S., JiangW.W., ClaybourneQ., TokumaruY., LeeJ., GoldenbergD., Garrett-MayerE., GoodmanS., MoonC.S., KochW., WestraW.H., SidranskyD. and CalifanoJ.A., Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma, Clin Cancer Res14 (2008), 97-107.
17.
SinhaP., BahadurS., ThakarA., MattaA., MachaM., RalhanR. and GuptaS.D., Significance of promoter hypermethylation of p16 gene for margin assessment in carcinoma tongue, Head Neck31 (2009), 1423-30.
18.
KwonM.J., KwonJ.H., NamE.S., ShinH.S., LeeD.J., KimJ.H., RhoY.S., SungC.O., LeeW.J. and ChoS.J., TWIST1 promoter methylation is associated with prognosis in tonsillar squamous cell carcinoma, Hum Pathol44 (2013), 1722-9.
19.
RohJ.L., WangX.V., ManolaJ., SidranskyD., ForastiereA.A. and KochW.M., Clinical correlates of promoter hypermethylation of four target genes in head and neck cancer: a cooperative group correlative study, Clin Cancer Res19 (2013), 2528-40.
20.
ArantesL.M., de CarvalhoA.C., MelendezM.E., CentroneC.C., Gois-FilhoJ.F., ToporcovT.N., CalyD.N., TajaraE.H., Goloni-BertolloE.M., CarvalhoA.L.and Gencapo, Validation of methylation markers for diagnosis of oral cavity cancer, Eur J Cancer51 (2015), 632-41.
21.
JungH.M., PhillipsB.L., PatelR.S., CohenD.M., JakymiwA., KongW.W., ChengJ.Q. and ChanE.K., Keratinization-associated miR-7 and miR-21 regulate tumor suppressor reversion-inducing cysteine-rich protein with kazal motifs (RECK) in oral cancer, J Biol Chem287 (2012), 29261-72.
22.
SvedlundJ., Koskinen EdblomS., MarquezV.E., AkerstromG., BjorklundP. and WestinG., Hypermethylated in cancer 1 (HIC1), a tumor suppressor gene epigenetically deregulated in hyperparathyroid tumors by histone H3 lysine modification, J Clin Endocrinol Metab97 (2012), E1307-15.
23.
MarcinkiewiczK.M. and GudasL.J., Altered histone mark deposition and DNA methylation at homeobox genes in human oral squamous cell carcinoma, J Cell Physiol229 (2014), 1405-16.
24.
ChangC.C., LinB.R., ChenS.T., HsiehT.H., LiY.J. and KuoM.Y., HDAC2 promotes cell migration/invasion abilities through HIF-1alpha stabilization in human oral squamous cell carcinoma, J Oral Pathol Med40 (2011), 567-75.
25.
SakumaT., UzawaK., OndaT., ShiibaM., YokoeH., ShibaharaT. and TanzawaH., Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma, Int J Oncol29 (2006), 117-24.
26.
XiaR., ZhouR., TianZ., ZhangC., WangL., HuY., HanJ. and LiJ., High expression of H3K9me3 is a strong predictor of poor survival in patients with salivary adenoid cystic carcinoma, Arch Pathol Lab Med137 (2013), 1761-9.
27.
TzaoC., TungH.J., JinJ.S., SunG.H., HsuH.S., ChenB.H., YuC.P. and LeeS.C., Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus, Mod Pathol22 (2009), 252-60.
28.
MatheE.A., NguyenG.H., BowmanE.D., ZhaoY., BudhuA., SchetterA.J., BraunR., ReimersM., KumamotoK., HughesD., AltorkiN.K., CassonA.G., LiuC.G., WangX.W., YanaiharaN., HagiwaraN., DannenbergA.J., MiyashitaM., CroceC.M. and HarrisC.C., MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival, Clin Cancer Res15 (2009), 6192-200.
29.
LoW.Y., WangH.J., ChiuC.W. and ChenS.F., miR-27b-regulated TCTP as a novel plasma biomarker for oral cancer: from quantitative proteomics to post-transcriptional study, J Proteomics77 (2012), 154-66.
30.
WuY.Y., ChenY.L., JaoY.C., HsiehI.S., ChangK.C. and HongT.M., miR-320 regulates tumor angiogenesis driven by vascular endothelial cells in oral cancer by silencing neuropilin 1, Angiogenesis17 (2014), 247-60.
31.
LiuN., CuiR.X., SunY., GuoR., MaoY.P., TangL.L., JiangW., LiuX., ChengY.K., HeQ.M., ChoW.C., LiuL.Z., LiL. and MaJ., A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma, Int J Cancer134 (2014), 1359-68.
32.
YuB.L., PengX.H., ZhaoF.P., LiuX., LuJ., WangL., LiG., ChenH.H. and LiX.P., MicroRNA-378 functions as an onco-miR in nasopharyngeal carcinoma by repressing TOB2 expression, Int J Oncol44 (2014), 1215-22.
33.
VietC.T. and SchmidtB.L., Methylation array analysis of preoperative and postoperative saliva DNA in oral cancer patients, Cancer Epidemiol Biomarkers Prev17 (2008), 3603-11.
34.
OvchinnikovD.A., CooperM.A., PanditP., ComanW.B., Cooper-WhiteJ.J., KeithP., WolvetangE.J., SloweyP.D. and PunyadeeraC., Tumor-suppressor Gene Promoter Hypermethylation in Saliva of Head and Neck Cancer Patients, Transl Oncol5 (2012), 321-6.
35.
ChenY.W., KaoS.Y., WangH.J. and YangM.H., Histone modification patterns correlate with patient outcome in oral squamous cell carcinoma, Cancer119 (2013), 4259-67.
36.
PiscopoM., CampisiG., ColellaG., BilancioneM., CaccamoS., Di LibertoC., TartaroG.P., GiovannelliL., PulcranoG. and FucciL., H3 and H3.3 histone mRNA amounts and ratio in oral squamous cell carcinoma and leukoplakia, Oral Dis12 (2006), 130-6.
